Quantumzyme's Cash Dries Up Amidst Persistent Losses

TL;DR

**QGAI is a zombie company with no revenue and $184 in cash; avoid at all costs as a going concern risk looms large.**

AI Summary

Quantumzyme Corp. (QGAI) reported a net loss of $49,868 for the quarter ended October 31, 2025, a 23.9% improvement from the $65,523 net loss in the same period of 2024. The company generated no revenue in either period. Operating expenses decreased to $39,196 from $60,934 year-over-year, primarily due to a significant reduction in professional fees from $59,357 in Q3 2024 to $23,094 in Q3 2025. However, general and administrative expenses increased from $1,577 to $16,102. Interest expense rose to $10,672 from $4,589. QGAI's cash balance plummeted to $184 as of October 31, 2025, from $584 on July 31, 2025, and the company reported an accumulated deficit of $5,686,435. Total liabilities increased to $490,769 from $441,301, driven by a rise in notes payable to $268,594 from $249,081. The company explicitly stated a 'going concern' risk due to its net losses, accumulated deficit, and dependence on external funding, with no firm agreements for future financing.

Why It Matters

Quantumzyme's continued net losses and dwindling cash balance to just $184 raise significant red flags for investors, indicating severe operational challenges and an unsustainable financial model. The explicit 'going concern' warning underscores the high risk of business failure without immediate and substantial external funding, which could lead to a complete loss for shareholders. In a competitive biotransformation sector, QGAI's inability to generate revenue or secure financing puts it at a severe disadvantage against better-capitalized rivals, impacting its ability to develop and commercialize its 'Enzyme Catalyst' assets. Employees face job insecurity, and potential customers may be wary of engaging with a company on the brink.

Risk Assessment

Risk Level: high — The company explicitly states a 'going concern' risk due to net losses of $49,868, an accumulated deficit of $5,686,435, and cash used in operations of $19,913 for the quarter ended October 31, 2025. Its cash balance is a mere $184, and it has no firm agreements for future financing, indicating an extremely precarious financial position.

Analyst Insight

Investors should immediately divest any holdings in QGAI. The company's 'going concern' warning, near-zero cash balance of $184, and lack of revenue generation signal an extremely high risk of insolvency and potential delisting. There is no clear path to profitability or sustainable operations.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$184

total Debt

$490,769

net Income

-$49,868

eps

$0.00

gross Margin

N/A

cash Position

$184

revenue Growth

0.0%

Key Numbers

• $184 — Cash balance (As of October 31, 2025, down from $584 on July 31, 2025, indicating severe liquidity issues.)
• $49,868 — Net loss (For the quarter ended October 31, 2025, a persistent loss with no revenue.)
• $5,686,435 — Accumulated deficit (As of October 31, 2025, highlighting significant historical losses.)
• $0 — Sales revenue (For both the quarters ended October 31, 2025, and 2024, indicating no operational income.)
• $268,594 — Notes payable (As of October 31, 2025, an increase from $249,081 on July 31, 2025, contributing to rising liabilities.)
• $19,913 — Net cash used in operating activities (For the quarter ended October 31, 2025, further depleting cash reserves.)
• 38,962,050 — Common shares outstanding (As of December 15, 2025, and October 31, 2025.)
• $39,196 — Total operating expenses (For the quarter ended October 31, 2025, a decrease from $60,934 in the prior year, but still significant without revenue.)

Key Players & Entities

• Quantumzyme Corp. (company) — registrant of the 10-Q filing
• Reliant Services, Inc. (company) — former name of Quantumzyme Corp.
• Naveen Krishna Rao Kulkarni (person) — sole-officer and director of Quantumzyme Corp. since February 8, 2023, and seller of assets to the company
• Sandra (Demeria) Brossart (person) — former sole-officer and director of Quantumzyme Corp. until February 8, 2023
• SEC (regulator) — recipient of the 10-Q filing
• Nevada (company) — state of incorporation for Quantumzyme Corp.
• Quantumzyme Inc. (company) — Delaware corporation from which Quantumzyme Corp. acquired assets
• US Dollar (dollar_amount) — functional currency of Quantumzyme Corp.

FAQ

Risk Factors

• Severe Liquidity Constraints [high — financial]: The company's cash balance has drastically reduced to $184 as of October 31, 2025, from $584 on July 31, 2025. This severe depletion, coupled with no revenue generation, poses an immediate threat to ongoing operations.
• Persistent Net Losses and Accumulated Deficit [high — financial]: Quantumzyme reported a net loss of $49,868 for the quarter ended October 31, 2025, contributing to an accumulated deficit of $5,686,435. This indicates a long-term inability to generate profits.
• Dependence on External Financing [high — financial]: The company explicitly states a 'going concern' risk due to its financial condition and dependence on external funding. There are no firm agreements for future financing, creating significant uncertainty.
• Lack of Revenue Generation [high — operational]: Quantumzyme generated no sales revenue in the quarter ended October 31, 2025, nor in the comparable period of 2024. This lack of commercial activity is a fundamental business risk.
• Increasing Liabilities [medium — financial]: Total liabilities increased to $490,769 as of October 31, 2025, from $441,301 on July 31, 2025. This rise is primarily driven by an increase in notes payable to $268,594.
• Rising General and Administrative Expenses [medium — operational]: Despite a reduction in total operating expenses, general and administrative expenses increased significantly from $1,577 to $16,102 year-over-year, indicating potential inefficiencies or increased overhead without corresponding revenue.
• Increasing Interest Expense [medium — financial]: Interest expense rose to $10,672 from $4,589 year-over-year, reflecting a higher debt burden or increased interest rates on existing debt, further straining profitability.

Industry Context

Quantumzyme Corp. operates in a highly competitive biotechnology or life sciences sector, characterized by long development cycles, significant R&D investment, and high failure rates. Companies in this space often rely heavily on external funding, including venture capital and public markets, to sustain operations until a product reaches commercialization. The industry faces stringent regulatory hurdles and requires continuous innovation to stay relevant.

Regulatory Implications

As a company with significant financial distress and a stated 'going concern' risk, Quantumzyme is subject to heightened scrutiny from regulatory bodies like the SEC. Continued failure to demonstrate a path to profitability or secure financing could lead to delisting from exchanges and potential investigations into financial reporting practices.

What Investors Should Do

1. Avoid investment
2. Monitor for financing news
3. Review future 10-Q filings for operational changes

Key Dates

• 2025-10-31: Quarter End — Reporting period for the 10-Q, showing a net loss of $49,868 and a cash balance of $184.
• 2025-07-31: Previous Quarter End — Comparison point for balance sheet items, showing a cash balance of $584 and total liabilities of $441,301.
• 2024-10-31: Prior Year Quarter End — Comparison point for the statement of operations, showing a net loss of $65,523 and total operating expenses of $60,934.

Glossary

Accumulated deficit

The total net losses of a company over its lifetime that have not been offset by net income. (Indicates Quantumzyme's long-term unprofitability, with a deficit of $5,686,435 as of October 31, 2025.)

Going concern

A business's ability to continue operating for the foreseeable future without the threat of liquidation. (Quantumzyme explicitly states this risk due to its financial condition, highlighting severe doubt about its survival.)

Notes payable

Short-term or long-term debt obligations that a company owes to lenders, typically documented by a promissory note. (Increased to $268,594 as of October 31, 2025, contributing to the company's rising total liabilities.)

Operating expenses

Costs incurred by a company in its normal course of business, excluding costs of goods sold. (Decreased to $39,196 for the quarter ended October 31, 2025, but still a significant outflow without any revenue.)

Professional fees

Fees paid to external professionals such as lawyers, accountants, or consultants. (Significantly reduced from $59,357 to $23,094, a key driver of the decrease in total operating expenses.)

General and administrative expenses

Costs associated with the overall management and administration of a company, not directly tied to production or sales. (Increased substantially from $1,577 to $16,102, a concerning trend given the lack of revenue.)

Year-Over-Year Comparison

Compared to the prior year's quarter, Quantumzyme Corp. (QGAI) has reduced its net loss by 23.9% to $49,868, primarily due to a significant decrease in professional fees from $59,357 to $23,094. However, this improvement is overshadowed by a drastic decline in cash from $584 to $184, a substantial increase in general and administrative expenses from $1,577 to $16,102, and rising interest expenses. The company continues to generate no revenue, and its accumulated deficit has grown, reinforcing its precarious financial position and 'going concern' status.

Filing Documents

• qtzm_10q.htm (10-Q) — 405KB
• qtzm_ex311.htm (EX-31.1) — 10KB
• qtzm_ex321.htm (EX-32.1) — 4KB
• 0001477932-25-008968.txt ( ) — 2126KB
• relia-20251031.xsd (EX-101.SCH) — 26KB
• relia-20251031_lab.xml (EX-101.LAB) — 137KB
• relia-20251031_cal.xml (EX-101.CAL) — 22KB
• relia-20251031_pre.xml (EX-101.PRE) — 109KB
• relia-20251031_def.xml (EX-101.DEF) — 60KB
• qtzm_10q_htm.xml (XML) — 266KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1. Condensed Financial Statements. 4 CONDENSED BALANCE SHEETS 4 CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) 5 CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) 7 CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT (UNAUDITED) 6 NOTES TO CONDENSED FINANCIAL STATEMENTS (UNAUDITED) 8 Item 2.

Management's Discussion and Analysis of Financial Conditions and Results of Operations

Management's Discussion and Analysis of Financial Conditions and Results of Operations. 14 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk. 16 Item 4.

Controls and Procedures

Controls and Procedures. 16

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1. Legal Proceedings. 18 Item 1A. Risk Factors. 18 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 18 Item 3. Defaults Upon Senior Securities. 18 Item 4. Mine Safety Disclosures. 18 Item 5. Other Information. 18 Item 6. Exhibits. 19 2 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING INFORMATION This quarterly report on Form 10-Q and other publicly available documents, including the documents incorporated herein by reference, contain, and our officers and representatives may from time to time make, "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "believe," "expect," "future," "likely," "may," "plan," "seek," "will" and similar references to future periods actions or results. Examples of forward-looking statements include our prospects for one or more future material transactions, potential sources of financing, and expenses for future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this quarterly report on Form 10-Q is based only on information currently available to us

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Condensed Financial Statements

Item 1. Condensed Financial Statements. QUANTUMZYME CORP. (FORMALLY RELIANT SERVICES, INC.) CONDENSED BALANCE SHEETS October 31, 2025 July 31, 2025 ASSETS (Unaudited) Cash $ 184 $ 584 Prepaid expenses - - Total current assets 184 584 Total assets $ 184 $ 584 LIABILITIES AND STOCKHOLDERS' DEFICIT Current liabilities Accounts payable and accrued expenses $ 205,573 $ 175,218 Due to related parties 16,602 17,002 Notes payable 268,594 249,081 Total current liabilities 490,769 441,301 Total liabilities 490,769 441,301 Commitments and Contingencies (See note 5) - - STOCKHOLDERS' DEFICIT Preferred Shares 130,000,000 authorized shares, par value $ 0.00001 0 shares issued and outstanding as of October 31, 2025 and July 31, 2025, respectively - - Series A Preferred Shares 10,000,000 authorized shares, par value $ 0.00001 0 shares issued and outstanding as of October 31, 2025 and July 31, 2025 respectively - - Series B Preferred Shares 10,000,000 authorized shares, par value $ 0.00001 500 shares issued and outstanding as of October 31, 2025 and July 31, 2025, respectively 5 5 Common Shares 750,000,000 authorized shares, par value $ 0.00001 ; 38,962,050 and 38,962,050 shares issued and outstanding as of October 31, 2025 and July 31, 2025, respectively 389 389 Additional paid-in capital 5,195,456 5,195,456 Accumulated deficit ( 5,686,435 ) ( 5,636,567 ) Total stockholders' deficit ( 490,585 ) ( 440,717 ) Total liabilities and stockholders' deficit $ 184 $ 584 The accompanying notes are an integral part of these unaudited condensed financial statements. 4 Table of Contents QUANTUMZYME CORP. (FORMALLY RELIANT SERVICES, INC.) CONDENSED STATEMENTS OF OPERATIONS For the quarter ended October 31 2025 2024 (unaudited) (unaudited) Sales $ - $ - Operating expenses General and administrative 16,102 1,577 Professional fees 23,094 59,

Management's Discussion and Analysis of Financial Conditions and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Conditions and Results of Operations.

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS The following discussion may contain forward-looking statements regarding the Company, its business prospects and its results of operations that are subject to certain risks and uncertainties posed by many factors and events that could cause the Company's actual business, prospects and results of operations to differ materially from those that may be anticipated by such forward-looking statements. These forward-looking statements reflect our view only as of the date of this report. The Company cannot guarantee future results, levels of activity, performance, or achievement. The Company does not undertake any obligation to update or correct any forward-looking statements. Results of Operations for the three months ended October 31, 2025 and 2024 Revenues We earned no revenues for three mon

View Full Filing

View this 10-Q filing on SEC EDGAR